Targeting histone deacetylases for heart diseases

被引：4
|
作者：
Jin, Gang [1 ]
Wang, Kaiyue [1 ]
Zhao, Yaohui [1 ]
Yuan, Shuo [2 ]
He, Zhangxu [1 ]
Zhang, Jingyu [1 ]
机构：
[1] Henan Univ Chinese Med, Pharm Coll, Zhengzhou 450046, Peoples R China
[2] Zhengzhou Univ, Henan Childrens Hosp, Zhengzhou Childrens Hosp, Childrens Hosp, Zhengzhou 450018, Peoples R China
来源：
BIOORGANIC CHEMISTRY | 2023年 / 138卷
基金：
中国博士后科学基金;
关键词：
HDACs; Inhibitors; Heart diseases; ATTENUATES CARDIAC-HYPERTROPHY; CLASS-I; ANTITUMOR-ACTIVITY; ISCHEMIA/REPERFUSION INJURY; MINERALOCORTICOID RECEPTOR; BIOLOGICAL EVALUATION; ANTIFIBROTIC ACTIVITY; HDAC6; INHIBITOR; GENE-EXPRESSION; TRICHOSTATIN-A;
D O I：
10.1016/j.bioorg.2023.106601
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Histone deacetylases (HDACs) are responsible for the deacetylation of lysine residues in histone or non-histone substrates, leading to the regulation of many biological functions, such as gene transcription, translation and remodeling chromatin. Targeting HDACs for drug development is a promising way for human diseases, including cancers and heart diseases. In particular, numerous HDAC inhibitors have revealed potential clinical value for the treatment of cardiac diseases in recent years. In this review, we systematically summarize the therapeutic roles of HDAC inhibitors with different chemotypes on heart diseases. Additionally, we discuss the opportunities and challenges in developing HDAC inhibitors for the treatment of cardiac diseases.
引用
收藏
页数：12
相关论文
共 50 条
  • [1] Targeting histone deacetylases for heart failure
    Bush, Erik W.
    McKinsey, Timothy A.
    [J]. EXPERT OPINION ON THERAPEUTIC TARGETS, 2009, 13 (07) : 767 - 784
  • [2] Targeting Histone Deacetylases in Diseases: Where Are We?
    Benedetti, Rosaria
    Conte, Mariarosaria
    Altucci, Lucia
    [J]. ANTIOXIDANTS & REDOX SIGNALING, 2015, 23 (01) : 99 - 126
  • [3] Targeting histone deacetylases for the treatment of cancer and inflammatory diseases
    Huang, Lili
    [J]. JOURNAL OF CELLULAR PHYSIOLOGY, 2006, 209 (03) : 611 - 616
  • [4] Targeting Histone Deacetylases in Neuroblastoma
    Witt, O.
    Deubzer, H. E.
    Lodrini, M.
    Milde, T.
    Oehme, I.
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2009, 15 (04) : 436 - 447
  • [5] The role of histone deacetylases in cardiac energy metabolism in heart diseases
    Yu, Qingwen
    Zhao, Guangyuan
    Liu, Jingjing
    Peng, Yajie
    Xu, Xueli
    Zhao, Fei
    Shi, Yangyang
    Jin, Chengyun
    Zhang, Ji
    Wei, Bo
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 2023, 142
  • [6] Histone Deacetylases and Cardiometabolic Diseases
    Yiew, Kan Hui
    Chatterjee, Tapan K.
    Hui, David Y.
    Weintraub, Neal L.
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2015, 35 (09) : 1914 - 1919
  • [7] Targeting histone deacetylases for the treatment of disease
    Lawless, M. W.
    Norris, S.
    O'Byrne, K. J.
    Gray, S. G.
    [J]. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2009, 13 (05) : 826 - 852
  • [8] Advances in the Development of PET Ligands Targeting Histone Deacetylases for the Assessment of Neurodegenerative Diseases
    Tago, Tetsuro
    Toyohara, Jun
    [J]. MOLECULES, 2018, 23 (02):
  • [9] Epigenetics in sepsis: targeting histone deacetylases
    Ciarlo, Eleonora
    Savva, Athina
    Roger, Thierry
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2013, 42 : S8 - S12
  • [10] Dysregulation of histone deacetylases in ocular diseases
    Jae Hyun Jun
    Jun-Sik Kim
    Leon F. Palomera
    Dong-Gyu Jo
    [J]. Archives of Pharmacal Research, 2024, 47 (1) : 20 - 39
12345